Lysogene S.A.
Overview
Lysogene S.A. is a clinical-stage biopharmaceutical company focused on developing gene therapy treatments for patients with severe genetic disorders of the central nervous system. Specializing in diseases such as mucopolysaccharidosis type IIIA, the company is at the forefront of leveraging its expertise in gene therapy to address unmet medical needs.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Lysogene S.A. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.